AB Share Price

Open 14.95 Change Price %
High 15.24 1 Day -0.52 -3.46
Low 14.50 1 Week -0.12 -0.82
Close 14.50 1 Month -1.75 -10.77
Volume 115189 1 Year -4.17 -22.34
52 Week High 19.83
52 Week Low 9.09
AB Important Levels
Resistance 2 15.19
Resistance 1 14.90
Pivot 14.75
Support 1 14.10
Support 2 13.81
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
CS 23.50 0.90%
CS 23.50 0.90%
FP 46.48 -1.25%
FP 46.48 -1.25%
ACA 12.43 1.22%
More..
EPA France Top Gainers Stocks
MLONE 0.24 20.00%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
LEBL 1.63 -55.10%
LDL 26.90 -10.18%
LDL 26.90 -10.18%
BUI 10.95 -9.88%
BUI 10.95 -9.88%
BUI 10.95 -9.88%
FEM 27.33 -8.53%
FEM 27.33 -8.53%
FEM 27.33 -8.53%
ALFRE 0.92 -8.00%
More..

AB Science (EPA: AB)

AB Technical Analysis 1.5
As on 21st Apr 2017 AB Share Price closed @ 14.50 and we RECOMMEND Buy for LONG-TERM with Stoploss of 13.48 & Sell for SHORT-TERM with Stoploss of 15.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
AB Target for April
1st Target up-side 18.34
2nd Target up-side 19.89
3rd Target up-side 21.45
1st Target down-side 13.9
2nd Target down-side 12.35
3rd Target down-side 10.79
AB Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.ab-science.com
AB Address
AB
3, Avenue George V
Paris, 75008
France
Phone: 33 1 47 20 00 14
Fax: 33 1 47 20 24 11
AB Latest News
Interactive Technical Analysis Chart AB Science ( AB EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AB Science
AB Business Profile
AB Science S.A., a pharmaceutical company, engages in the research, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines in the United States and Europe. Its lead compound includes Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. The company focuses on therapies for the treatment of cancer, inflammatory diseases, and central nervous system diseases. It is also pursuing eight on-going phase III studies in human medicine in GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, mastocytosis, severe persistent asthma, rheumatoid arthritis, and progressive multiple sclerosis. The company markets its Masitinib under the Masivet brand name for the veterinary market in Europe. Its products are used by hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.